摘要
目的 观察缬沙坦对高血压 (EH)患者纤溶系统的影响。方法 选用 3 2例EH患者 ,给予缬沙坦治疗 8周 ,测定服药前后血压、血浆中纤溶酶原激活剂 (t-PA)含量及纤溶酶原激活剂抑制物 (PAI -I)含量 ,并与正常人作对照。结果 治疗前EH患者的血浆t-PA含量明显低于正常人 (P〈0 .0 1〉 ,而PAI-I含量明显高于正常人 (P〈0 .0 1〉 ,缬沙坦治疗 8周后 ,血压明显下降 (P〈0 .0 1〉 ,血浆中t-PA含量显著上升 (P〈0 .0 1〉 ,而PAI -I含量明显降低 (P〈0 .0 5〉 ,接近正常。结论 EH患者存在纤溶功能异常 ,缬沙坦在降压的同时 。
Objective To investigate the effect of valsartan on fibrinolytic activity in essential hypertensive(EH)patients.Methods Thrity-two EH patients were given valsartan 80 or 160mg qd for eight weeks.Blood pressure,as well as the plasma t-PA and PAI-I were measured before and after valsartan treatment,and those date were compared with normal healthy persons (NC group).Results Before treatment,the plasma t-PA was decreased and PAI-I was increased in EH group compared with NC group(P<0.01).After treatment,the average level of blood pressure was significantly decreased(P<0.01),the content of tPA was elevated,but content of PAI-I was decreased.Conclusions There were abnormal fibrinolytic activities in hypertensive patients,valsartan possesses of reducing blood pressure and improving fibrinolytic activity.
出处
《心脑血管病防治》
2003年第1期11-12,共2页
CARDIO-CEREBROVASCULAR DISEASE PREVENTION AND TREATMENT